Corgenix Announces Partnership with Health Diagnostic Laboratory

News Oct 31, 2013

The Laboratory Developed Test (LDT) would be based on Corgenix’ patented proprietary atherosclerosis biomarker technology for potential use in assessing heart disease risk.

Under terms of the multi-year agreement, HDL, Inc. has the rights to use Corgenix technology to develop, validate and offer a clinical LDT that may assist clinicians in predicting an increased risk for heart disease in various patient populations. The initial term of the agreement is three years, with annual renewals thereafter based on certain performance requirements.

“This strategic partnership continues our path to fully realize the commercial value of our technology,” said Douglass Simpson, President and CEO of Corgenix. “Our company looks forward to this beneficial partnership, which aims to expand the clinical utility of this advanced cardiac disease biomarker.”

“Our partnership with Corgenix fits perfectly with our strategy to develop best-of-breed biomarkers for the most comprehensive risk factor testing for cardiovascular disease and related diseases,” said Tonya Mallory, President and CEO of HDL, Inc.

LDT’s are at the leading edge of the personalized medicine movement, which includes testing that enables targeted pharmacologic treatment for, and prevention of, heart disease, cancer and other diseases.

Corgenix originally licensed the technology in 2002, and has applied this proprietary technology to the FDA-cleared anti-AtherOx® IgG test kit.

Blood-brain Barrier Breakdown Early Marker of Human Cognitive Dysfunction

News

Individuals with early cognitive function develop brain capillary damage and blood-brain barrier breakdown in the hippocampus, regardless of amyloid beta/tau biomarker changes.

Costs and Complications of Lung Cancer Diagnostic Tests Underestimated

News

This study underscores the importance of sharing risks with patients considering lung cancer screening.

Comprehensive New Way to Predict Breast Cancer Risk

News

Scientists have created the most comprehensive method yet to predict a woman’s risk of breast cancer, according to a study by Cancer Research UK published in Genetics in Medicine.

Like what you just read? You can find similar content on the communities below.

Diagnostics Proteomics & Metabolomics Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free